DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.142 EUR | -4.99% |
|
-8.49% | -38.24% |
| 31/05 | European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower | MT |
| 31/05 | DBV Technologies Says ADS Ratio Change to be Effective June 7 | MT |
| Sales 2024 * | 63.73L 69.16L 57Cr | Sales 2025 * | 49.76L 54L 45Cr | Capitalization | 11Cr 12Cr 990.84Cr |
|---|---|---|---|---|---|
| Net income 2024 * | -12Cr -14Cr -1.13TCr | Net income 2025 * | -12Cr -13Cr -1.06TCr | EV / Sales 2024 * | -8.66 x |
| Net cash position 2024 * | 17Cr 18Cr 1.49TCr | Net cash position 2025 * | 23Cr 24Cr 2.04TCr | EV / Sales 2025 * | -23.3 x |
| P/E ratio 2024 * |
-0.83
x | P/E ratio 2025 * |
-1.49
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | -4.99% | ||
| 1 week | -8.49% | ||
| 1 month | -6.24% | ||
| 3 months | -17.72% | ||
| 6 months | -18.83% | ||
| Current year | -38.24% |
1 week
1.12
1.28
1 month
1.121.48
Current year
1.101.90
1 year
1.103.92
3 years
1.1010.90
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 29/18/29 |
| Director of Finance/CFO | 54 | 06/11 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 22/19/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 62 | 01/21/01 |
Michel de Rosen
CHM | Chairman | 73 | 22/18/22 |
Don Soland
BRD | Director/Board Member | 65 | 06/15/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 1.142 | -4.99% | 184,135 |
| 30/24/30 | 1.202 | -1.48% | 133,036 |
| 29/24/29 | 1.22 | -.--% | 41,649 |
| 28/24/28 | 1.22 | -1.61% | 77,807 |
| 27/24/27 | 1.24 | -0.64% | 59,990 |
Real-time Euronext Paris, May 31, 2024 at 09:05 pm IST
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
29/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.142
EUR
Average target price
9.467
EUR
Spread / Average Target
+728.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.24% | 12Cr | |
| +15.54% | 7.85TCr | |
| +12.76% | 900.15Cr | |
| +58.17% | 496.1Cr | |
| -14.94% | 483.61Cr | |
| -.--% | 372.43Cr | |
| -26.63% | 218.54Cr | |
| +16.75% | 211.67Cr | |
| -37.97% | 194.2Cr | |
| -0.50% | 164.41Cr |
- Stock Market
- Equities
- DBV Stock
